QD Quadramed Corp.

QuadraMed� Corporation (Amex:QD) today announced that the company expects to complete beta testing of Affinity� Pharmacy v3.15 in December, and is targeting general availability for clients in January 2007. The product enhancements in regulatory, integration, technical and interface functionality developed for this release will help Affinity HIS (Healthcare Information System) and QuadraMed Long Term Care Pharmacy users improve patient safety and meet new prescription reporting requirements. QuadraMed will be previewing Affinity Pharmacy v3.15 at the ASHP (American Society of Health-System Pharmacists) Midyear Clinical Meeting and Exhibition, December 3-7, in Anaheim, California, Booth 2710. The five healthcare facilities completing beta testing of Affinity Pharmacy v3.15 report the product�s capabilities for variable dosing and improved paper MAR content are particularly effective. This version enables pharmacists to create predefined drug dosing parameters and attached them to a formulary item and predefined orders. These parameters can be modified for all types of orders before saving or activating them, then viewed and/or printed on reports, such as MARs, that display medication orders. QuadraMed clients using Affinity Pharmacy v3.15 will experience increased Medication Reconciliation functionality for greater patient safety and improved quality of care. These users will have the ability to automatically capture nursing information from the bedside, reducing the possibility of ADEs (adverse drug events) by eliminating the need to re-enter key patient information by the pharmacy department. The software also provides complete prescription reports for facility Admissions departments, transfers from one level of care to another, and a discharge report for clinicians. QuadraMed plans to beta test a further enhancement for Affinity Pharmacy in early 2007. It will feature the capability to generate a Patient Discharge Report, thereby helping clients meet a JCAHO 2007 Medication Reconciliation goal for this functionality. Of special interest to long-term care providers, including mental health facilities using QuadraMed Long Term Care Pharmacy with v3.15 enhancements, are redesigned charges, prescription refill history and third party billing, which will streamline billing to multiple Medicare Part D payers. The software will feature provision for a new data element, the National Provider Identification (NPI) number, to be used in billing and claims adjudication for federal and state transactions. Also included are the new fields required by ASAP (American Society for Automation in Pharmacy) rules-based standards, and the related ASAP Code Set, to support reporting for state prescription (controlled substance) monitoring programs. QuadraMed Pharmacy products are part of the Affinity care management product suite, a key foundational component of QuadraMed�s Care-Based Revenue Cycle� process. This strategic process enables healthcare organizations to achieve improved financial performance by leveraging quality of care into positive financial outcomes, while providing interoperability for the connected healthcare community and quality measurement. For information about all QuadraMed products and services, visit www.quadramed.com or call 800-393-0278. About QuadraMed Corporation QuadraMed Corporation advances the success of healthcare organizations through IT solutions that leverage quality care into positive financial outcomes. As evolving reimbursement scenarios challenge healthcare organizations to leverage quality of care into payment, clients committing to QuadraMed�s care-based solutions can realize market leading financial performance. Using QuadraMed�s end-to-end solutions to optimize the patient experience and leverage quality of care into payment, our clients can receive the proper reimbursement, in the shortest time, at the lowest administrative cost. Behind our products and services is a staff of almost 600 professionals whose experience and dedication to service have earned QuadraMed the trust and loyalty of customers at approximately 2,000 healthcare provider facilities. To find out more about QuadraMed, visit www.quadramed.com. Cautionary Statement on Risks Associated with QuadraMed�s Forward-Looking Statements This press release contains forward-looking statements, as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, by QuadraMed that are subject to risks and uncertainties. The words "believe," "expect," "anticipate," "intend," "plan," "estimate," "may," "should," "could," and similar expressions are intended to identify such statements. Forward-looking statements are not guarantees of future performance and are to be interpreted only as of the date on which they are made. QuadraMed undertakes no obligation to update or revise any forward-looking statement except as required by law. QuadraMed advises investors that it discusses risk factors and uncertainties that could cause QuadraMed�s actual results to differ from forward-looking statements in its periodic reports filed with the Securities and Exchange Commission ("SEC"). QuadraMed�s SEC filings can be accessed through the Investor Relations section of our website, www.quadramed.com, or through the SEC�s EDGAR Database at www.sec.gov (QuadraMed has EDGAR CIK No. 0001018833). QuadraMed and Affinity are registered trademarks of QuadraMed Corporation. Care-Based Revenue Cycle is a trademark of QuadraMed Corporation. All other trademarks are the property of their respective holders. QuadraMed(R) Corporation (Amex:QD) today announced that the company expects to complete beta testing of Affinity(R) Pharmacy v3.15 in December, and is targeting general availability for clients in January 2007. The product enhancements in regulatory, integration, technical and interface functionality developed for this release will help Affinity HIS (Healthcare Information System) and QuadraMed Long Term Care Pharmacy users improve patient safety and meet new prescription reporting requirements. QuadraMed will be previewing Affinity Pharmacy v3.15 at the ASHP (American Society of Health-System Pharmacists) Midyear Clinical Meeting and Exhibition, December 3-7, in Anaheim, California, Booth 2710. The five healthcare facilities completing beta testing of Affinity Pharmacy v3.15 report the product's capabilities for variable dosing and improved paper MAR content are particularly effective. This version enables pharmacists to create predefined drug dosing parameters and attached them to a formulary item and predefined orders. These parameters can be modified for all types of orders before saving or activating them, then viewed and/or printed on reports, such as MARs, that display medication orders. QuadraMed clients using Affinity Pharmacy v3.15 will experience increased Medication Reconciliation functionality for greater patient safety and improved quality of care. These users will have the ability to automatically capture nursing information from the bedside, reducing the possibility of ADEs (adverse drug events) by eliminating the need to re-enter key patient information by the pharmacy department. The software also provides complete prescription reports for facility Admissions departments, transfers from one level of care to another, and a discharge report for clinicians. QuadraMed plans to beta test a further enhancement for Affinity Pharmacy in early 2007. It will feature the capability to generate a Patient Discharge Report, thereby helping clients meet a JCAHO 2007 Medication Reconciliation goal for this functionality. Of special interest to long-term care providers, including mental health facilities using QuadraMed Long Term Care Pharmacy with v3.15 enhancements, are redesigned charges, prescription refill history and third party billing, which will streamline billing to multiple Medicare Part D payers. The software will feature provision for a new data element, the National Provider Identification (NPI) number, to be used in billing and claims adjudication for federal and state transactions. Also included are the new fields required by ASAP (American Society for Automation in Pharmacy) rules-based standards, and the related ASAP Code Set, to support reporting for state prescription (controlled substance) monitoring programs. QuadraMed Pharmacy products are part of the Affinity care management product suite, a key foundational component of QuadraMed's Care-Based Revenue Cycle(TM) process. This strategic process enables healthcare organizations to achieve improved financial performance by leveraging quality of care into positive financial outcomes, while providing interoperability for the connected healthcare community and quality measurement. For information about all QuadraMed products and services, visit www.quadramed.com or call 800-393-0278. About QuadraMed Corporation QuadraMed Corporation advances the success of healthcare organizations through IT solutions that leverage quality care into positive financial outcomes. As evolving reimbursement scenarios challenge healthcare organizations to leverage quality of care into payment, clients committing to QuadraMed's care-based solutions can realize market leading financial performance. Using QuadraMed's end-to-end solutions to optimize the patient experience and leverage quality of care into payment, our clients can receive the proper reimbursement, in the shortest time, at the lowest administrative cost. Behind our products and services is a staff of almost 600 professionals whose experience and dedication to service have earned QuadraMed the trust and loyalty of customers at approximately 2,000 healthcare provider facilities. To find out more about QuadraMed, visit www.quadramed.com. Cautionary Statement on Risks Associated with QuadraMed's Forward-Looking Statements This press release contains forward-looking statements, as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, by QuadraMed that are subject to risks and uncertainties. The words "believe," "expect," "anticipate," "intend," "plan," "estimate," "may," "should," "could," and similar expressions are intended to identify such statements. Forward-looking statements are not guarantees of future performance and are to be interpreted only as of the date on which they are made. QuadraMed undertakes no obligation to update or revise any forward-looking statement except as required by law. QuadraMed advises investors that it discusses risk factors and uncertainties that could cause QuadraMed's actual results to differ from forward-looking statements in its periodic reports filed with the Securities and Exchange Commission ("SEC"). QuadraMed's SEC filings can be accessed through the Investor Relations section of our website, www.quadramed.com, or through the SEC's EDGAR Database at www.sec.gov (QuadraMed has EDGAR CIK No. 0001018833). QuadraMed and Affinity are registered trademarks of QuadraMed Corporation. Care-Based Revenue Cycle is a trademark of QuadraMed Corporation. All other trademarks are the property of their respective holders.